Cargando…

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

IMPORTANCE: Tumor measurements can be used to estimate time to nadir and depth of nadir as potential surrogates for overall survival (OS). OBJECTIVE: To assess time to nadir and depth of nadir as surrogates for OS in metastatic colorectal cancer. DESIGN, SETTING, AND PARTICIPANTS: Pooled analysis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burzykowski, Tomasz, Coart, Elisabeth, Saad, Everardo D., Shi, Qian, Sommeijer, Dirkje W., Bokemeyer, Carsten, Díaz-Rubio, Eduardo, Douillard, Jean-Yves, Falcone, Alfredo, Fuchs, Charles S., Goldberg, Richard M., Hecht, J. Randolph, Hoff, Paulo M., Hurwitz, Herbert, Kabbinavar, Fairooz F., Koopman, Miriam, Maughan, Timothy S., Punt, Cornelis J. A., Saltz, Leonard, Schmoll, Hans-Joachim, Seymour, Matthew T., Tebbutt, Niall C., Tournigand, Christophe, Van Cutsem, Eric, de Gramont, Aimery, Zalcberg, John R., Buyse, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6755539/ https://www.ncbi.nlm.nih.gov/pubmed/31539075 http://dx.doi.org/10.1001/jamanetworkopen.2019.11750

Ejemplares similares

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
por: Yin, Jun, et al.
Publicado: (2021)

Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
por: Ou, Fang-Shu, et al.
Publicado: (2023)

Trial Design for Cancer Immunotherapy: A Methodological Toolkit
por: Saad, Everardo D., et al.
Publicado: (2023)

The case against censoring of progression-free survival in cancer clinical trials – A pandemic shutdown as an illustration
por: Jamoul, Corinne, et al.
Publicado: (2022)

Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies
por: Cassidy, James, et al.
Publicado: (2009)

MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER
por: Dufresne, Armelle, et al.
Publicado: (2008)

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
por: McCleary, Nadine J, et al.
Publicado: (2022)

Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report
por: Van Cutsem, Eric, et al.
Publicado: (2017)

Surrogacy Beyond Prognosis: The Importance of “Trial-Level” Surrogacy
por: Buyse, Marc, et al.
Publicado: (2022)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2015)

New curative approach using embolization followed by moderate-dose radiotherapy after surgical failure for large right heart metastasis
por: Delanian, Sylvie, et al.
Publicado: (2021)

HBI-8000, HUYABIO Lead Clinical Program, Is a Selective Histone Deacetylase Inhibitor With Therapeutic Benefits in Leukemia and in Solid Tumors
por: Shojaei, Farbod, et al.
Publicado: (2022)

The evaluation of surrogate endpoints
por: Burzykowski, Tomasz, et al.
Publicado: (2005)

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
por: Diouf, Momar, et al.
Publicado: (2014)

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group
por: Bleiberg, H., et al.
Publicado: (2017)

Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab
por: Ather, Ferdows, et al.
Publicado: (2013)

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
por: Garon, Edward B, et al.
Publicado: (2016)

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone
por: ten Hoorn, Sanne, et al.
Publicado: (2021)

Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer
por: Saad, Everardo Delforge, et al.
Publicado: (2020)

Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
por: Mésange, Paul, et al.
Publicado: (2014)

Clinical Value of Consensus Molecular Subtypes in Colorectal Cancer: A Systematic Review and Meta-Analysis
por: ten Hoorn, Sanne, et al.
Publicado: (2021)

The use of histopathological subtyping in patients with ampullary cancer: a nationwide analysis
por: de Bakker, Jacob, et al.
Publicado: (2022)

MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF(wt) metastatic colorectal cancer
por: Tabernero, J., et al.
Publicado: (2022)

Self-care, resilience, and caregiver burden in relatives of patients with advanced cancer: results from the eQuiPe study
por: van Roij, Janneke, et al.
Publicado: (2021)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

Evaluation of Systemic Treatments of Small Intestinal Adenocarcinomas: A Systematic Review and Meta-analysis
por: de Back, Tim, et al.
Publicado: (2023)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Central statistical monitoring of investigator-led clinical trials in oncology
por: Buyse, Marc, et al.
Publicado: (2020)

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
por: Auclin, Edouard, et al.
Publicado: (2019)

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
por: Chibaudel, Benoist, et al.
Publicado: (2020)

Endocrinological late effects after chemotherapy for testicular cancer.
por: Berger, C. C., et al.
Publicado: (1996)

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023)

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
por: Sugihara, Kenichi, et al.
Publicado: (2012)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016)

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
por: Bokemeyer, C., et al.
Publicado: (1994)

Analysis of blood coagulation in mice: pre-analytical conditions and evaluation of a home-made assay for thrombin-antithrombin complexes
por: Sommeijer, Dirkje W, et al.
Publicado: (2005)

MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial
por: Gormly, KLM, et al.
Publicado: (2015)

Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial
por: Okines, A, et al.
Publicado: (2009)

Long-term effects on sexual function and fertility after treatment of testicular cancer
por: Hartmann, J T, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_9b158tcjdrgoj7v63hr8gr15bm